Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells

Cui, Shu‐Xiang; Qu, Xian‐Jun; Gao, Zu–Hua; Zhang, Yusheng; Zhang, Xiaofan; Zhao, Cuirong; Xu, Wenfang; Li, Qian-Bin; Han, Jinxiang

doi:10.1016/j.canlet.2009.11.021

Cited by 39 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous study, CIP-13F was found to display the inhibitory eVect on APN/CD13 activity and cancer growth of human OVCA and hepatocellular carcinoma cell lines [9,21]. The inhibitory eVect of CIP-13F was greater than that of bestatin.…”

Section: Discussionmentioning

confidence: 97%

“…Chemicals CIP-13F, (S)-2-amino-N-((S)-1-(2-(hydroxyamino)-2-oxoethyl)-2,6-dioxopiperidin-3-yl)-3-phenylpropanamide hydrochloride, was designed and synthesized as described previously [9,14]. The purity of CIP-13F as measured by high-performance liquid chromatography (HPLC) was 99.8%.…”

Section: Methodsmentioning

confidence: 99%

“…A number of reports showed that APN/CD13 displays a key role in cancer progression by the regulation of processes such as cell-cell contact, proliferation, invasion and metastasis, and angiogenesis [7][8][9]. So far, bestatin is the only APN/CD13 inhibitor used clinically as an adjuvant in the treatment for malignancies such as leukemia and ovarian carcinoma and lung cancers [10,11].…”

Section: Introductionmentioning

confidence: 99%

“…Our previous studies suggested that CIP-13F displayed a great inhibitory eVect on activity and expression of APN/CD13 and ES-2 ovarian carcinoma growth [9]. CIP-13F has been considered as a potential candidate compound for the treatment for cancers with positive activity and expression of APN/CD13.…”

Section: Introductionmentioning

confidence: 99%

“…CIP-13F, a cyclic-imide peptidomimetics compound, was designed based on the X-ray structure of APN/CD13 and the reference drug bestatin [9,14]. Our previous studies suggested that CIP-13F displayed a great inhibitory eVect on activity and expression of APN/CD13 and ES-2 ovarian carcinoma growth [9].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

Pei

Yuan

Qin

et al. 2011

Cancer Chemother Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

Pei

Yuan

Qin

et al. 2011

Cancer Chemother Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

Most recent advances on enzyme‐activatable optical probes for bioimaging

Mei

Tian

2021

Aggregate

View full text Add to dashboard Cite

Enzymes are essential biological elements that play vital roles in many key cellular events and physiological processes. The dysregulation of enzyme activity broadly occurs in a large number of diseases ranging from inflammation to neurodegenerative disorders to tumors. Molecular imaging allows accurate and noninvasive visualization of biological analytes/physiological processes of interest closely linked to human health at different levels. Among various imaging modalities, optical imaging stands out benefited from its high sensitivity, excellent spatiotemporal resolution, real‐time mode, and facile accessibility. Diverse optical probes specifically activatable by disease‐relevant enzymes have sprung up. In comparison to the “always‐on” counterparts, the “off‐on” imaging probes activated by enzymes hold great promise for precise diagnosis of diseases at early stage with high target‐to‐background ratio, dramatically improved specificity, and significantly enhanced sensitivity. Herein, the most recent advances in optical probes activatable by enzymes for biosensing and bioimaging are briefly reviewed emphasizing their molecular design, working mechanism, and biomedical applications. Besides, some important prospects and the current challenges to fully implement the potential of enzyme‐activatable probes for precise and efficient theranostics in life science are also pointed out to hopefully arouse new insights into the development of new generation of theranostics.

show abstract

Enantioselective Synthesis of Glutarimide Alkaloids Cordiarimides A, B, Crotonimides A, B, and Julocrotine

et al. 2011

View full text Add to dashboard Cite

Five glutarimide alkaloids cordiarimide A (5), cordiarimide B (6), crotonimide A (3), crotonimide B (4), and julocrotine (2) have been synthesized starting from Boc-L-glutamine (7). The benzylic alcohol chiral centre of cordiarimides B (6) has been established in 6 : 1 diastereoselectivity by catalytic asymmetric hydrogenation using Zhou's catalytic system Pd(CF(3)CO(2))(2)/(R,R)-Me-DuPhos.National Natural Science Foundation of China[20832005]; National Basic Research Program (973 Program) of China[2010CB833200

show abstract

Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells

Cited by 39 publications

References 27 publications

CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

Most recent advances on enzyme‐activatable optical probes for bioimaging

Enantioselective Synthesis of Glutarimide Alkaloids Cordiarimides A, B, Crotonimides A, B, and Julocrotine

Contact Info

Product

Resources

About